I. Haeck

发表

Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitis.

M. D. de Bruin‐Weller, M. Knol, E. Knol, 2012, The Journal of investigative dermatology.

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry.

M. D. de Bruin‐Weller, M. Schuttelaar, M. Kamsteeg, 2020, Journal of the American Academy of Dermatology.

The Self‐Administered Eczema Area and Severity Index in Children with Moderate to Severe Atopic Dermatitis: Better Estimation of AD Body Surface Area Than Severity

M. Knol, S. Pasmans, C. Bruijnzeel-Koomen, 2010, Pediatric dermatology.

Low bone mineral density in adult patients with moderate to severe atopic dermatitis

M. D. de Bruin‐Weller, M. Knol, H. Verhaar, 2009, The British journal of dermatology.

Bone mineral density in children with moderate to severe atopic dermatitis.

M. D. de Bruin‐Weller, M. Knol, S. Pasmans, 2010, Journal of the American Academy of Dermatology.

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.

M. D. de Bruin‐Weller, A. Flinterman, M. Kamsteeg, 2022, JAMA dermatology.

Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis

M. D. de Bruin‐Weller, M. Knol, I. Haeck, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis.

M. D. de Bruin‐Weller, E. Knol, C. Bruijnzeel-Koomen, 2009, The Journal of allergy and clinical immunology.

Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis.

J. Lammers, M. D. de Bruin‐Weller, M. Knol, 2010, Journal of the American Academy of Dermatology.

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

M. D. de Bruin‐Weller, M. Graaf, M. Kamsteeg, 2020, Allergy.

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

M. D. de Bruin‐Weller, M. Schuttelaar, M. Kamsteeg, 2022, Acta dermato-venereologica.

Severe atopic dermatitis treated with everolimus

I. Haeck, S. V. van Velsen, C. Bruijnzeel‐Koomen, 2009, The Journal of dermatological treatment.

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

M. D. de Bruin‐Weller, A. Flinterman, M. Kamsteeg, 2021, Acta dermato-venereologica.

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

M. D. de Bruin‐Weller, M. Schuttelaar, F. Garritsen, 2022, Acta dermato-venereologica.

Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused

E. Buskens, M. D. de Bruin‐Weller, C. Bruijnzeel-Koomen, 2007, The British journal of dermatology.

Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.

M. D. de Bruin‐Weller, M. Knol, C. Bruijnzeel-Koomen, 2011, Journal of the American Academy of Dermatology.

Therapeutic challenges in atopic dermatitis

I. Haeck, 2010 .

First experience with enteric‐coated mycophenolate sodium (Myfortic®) in severe recalcitrant adult atopic dermatitis: an open label study

M. D. de Bruin‐Weller, I. Haeck, S. V. van Velsen, 2009, The British journal of dermatology.

Dupilumab facial redness: Positive effect of itraconazole

M. D. de Bruin‐Weller, L. Ariens, M. V. van Dijk, 2019, JAAD case reports.

Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts.

M. D. de Bruin‐Weller, C. Bruijnzeel-Koomen, I. Haeck, 2011, Journal of the American Academy of Dermatology.

Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis.

C. Bruijnzeel-Koomen, I. Haeck, S. V. van Velsen, 2010, Journal of the American Academy of Dermatology.

The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis

Marlise P. de Roos, R. Sparidans, I. Haeck, 2012, The Journal of dermatological treatment.

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

M. D. de Bruin‐Weller, M. Kamsteeg, M. de Graaf, 2023, Acta dermato-venereologica.

Two-year assessment of effect of topical corticosteroids on bone mineral density in adults with moderate to severe atopic dermatitis.

M. Knol, C. Bruijnzeel-Koomen, M. Lam, 2012, Journal of the American Academy of Dermatology.

Bone mineral density in patients with atopic dermatitis.

M. D. de Bruin‐Weller, C. Bruijnzeel-Koomen, I. Haeck, 2012, Chemical Immunology.

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis

M. D. de Bruin‐Weller, R. Schweizer, M. Kamsteeg, 2023, Clinical and translational allergy.